DIM WisdomTree International MidCap Dividend Fund

Regulatory News:

Sartorius Stedim Biotech S.A. (Paris:DIM):

       

€ in millions unlessotherwise specified

1st half2015

 

1st half2014

 

Growthin %

 

Growthin % const. fx

  Order intake 467.4   338.4   38.1   25.5 Sales revenue 422.0   324.1   30.2   18.7 EMEA1 192.5   162.7   18.3   16.0 The Americas1 149.3   97.9   52.6   26.2 Asia | Pacific1 80.3   63.6   26.1   14.0 EBITDA2 106.5   73.8   44.3     EBITDA margin2 in % 25.2   22.8         Net profit3 62.9   40.7   54.6     Earnings per share3 in € 4.10   2.65   54.6      

1 According to customers’ location2 Underlying EBITDA = earnings before interest, taxes, depreciation and amortization, and adjusted for extraordinary items3 Underlying net profit = net profit after non-controlling interest; adjusted for extraordinary items, non-cash amortization and based on a normalized financial result and tax rate

Strong double-digit topline growth

In the first half of 2015, Sartorius Stedim Biotech, a leading supplier for the biopharmaceutical industry, continued on the growth track: Driven by dynamic performance across the portfolio, order intake and sales revenue were up in double digits. All regions contributed to the strong gains in sales, with the Americas in the lead.

Profits on the rise

Sartorius Stedim Biotech reported an overproportionate increase in earnings, mainly driven by economies of scale and favorable currency effects. Underlying EBITDA rose 44.3% to 106.5 million euros; the corresponding margin reached 25.2%. Extraordinary expenses totaled 1.5 million euros. Underlying earnings per share were 4.10 euros, up year over year from 2.65 euros.

All key financial indicators at comfortable levels

The financial position of the Sartorius Stedim Biotech Group has remained strong and stable as reflected by an equity ratio of 58.0% and a ratio of net debt to underlying EBITDA of 0.6. Net debt at the end of the first half year was 111.3 million euros.

Outlook for 2015 raised

Based on the strong results of the first six months and the two recent acquisitions, management has upgraded its forecast for the full year of 2015. Sales revenue in constant currencies is now expected to increase approx. 15%, which includes approx. 1.5 percentage points from the acquisitions of BioOutsource and Cellca (prev. guidance: approx. 7% to 10% without acquisitions). The underlying EBITDA margin in constant currencies is forecasted to reach around 25.0% to 25.5% (prev. guidance: around 24.5% to 25.0%).

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

Conference call and webcast

Joachim Kreuzburg, CEO and Chairman of the Board of the Sartorius Stedim Biotech Group, will discuss the results with analysts and investors on Tuesday, July 21, 2015, at 3:30 p.m. Central European Time (CET), in a teleconference. You may dial into the teleconference starting at 3:20 p.m. CET at the following numbers:

Germany: +49(0)69 2222 10644France: +33(0)1 76 77 22 37UK: +44(0)20 3427 1936USA: +1646 254 3374

The dial-in code is: 2380307

To view the webcast or presentation, log onto: www.sartorius-stedim.com

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge products and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech has a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,700 people, and in 2014 earned sales revenue of 683.5 million euros.

__________________________________________________________________________________________

View source version on businesswire.com: http://www.businesswire.com/news/home/20150720006502/en/

Sartorius Corporate Administration GmbHPetra Kirchhoff, +49(0)551.308.1686Vice President of Corporate Communications and Investor RelationsFax: +49(0)551.308.3410E-mail: petra.kirchhoff@sartorius.comwww.sartorius-stedim.com